Skip to Main Content

An official website of the United States government

Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit  cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.

Pulmonary Adenocarcinoma of Low Malignant Potential

Principal Investigator
Name
Eric Burks
Degrees
MD
Institution
Boston University School Of Medicine
Position Title
Associate Professor
Email
About this CDAS Project
Study
NLST (Learn more about this study)
Project ID
NLST-867
Initial CDAS Request Approval
Jan 7, 2022
Title
Pulmonary Adenocarcinoma of Low Malignant Potential
Summary
Overdiagnosis in the CTLS arm of the NLST was associated with bronchoalveolar carcinoma (BAC). There was no central pathologic review for the NLST and BAC represented an entity whose criteria had been multiply revised and inconsistently applied before ultimately being abandoned by the IASLC and WHO after the NLST publication. More recently, my group has defined histologic criteria associated with indolent lung adenocarcinoma behavior after complete resection. This entity is termed "pulmonary adenocarcinoma of low malignant potential" and in combination with adenocarcinoma in situ (AIS) and minimally invasive adenocarcinoma (MIA) corresponded to a frequency similar to that of BAC among stage I adenocarcinoma in the CTLS arm of the NLST.

Yambayev I, Sullivan TB, Suzuki K, Zhao Q, Higgins SE, Yilmaz OH, Litle VR, Moreira P, Servais EL, Stock CT, Quadri SM, Williamson C, Rieger-Christ KM, Burks EJ. Pulmonary Adenocarcinomas of Low Malignant Potential: Proposed Criteria to Expand the Spectrum Beyond Adenocarcinoma In Situ and Minimally Invasive Adenocarcinoma. Am J Surg Pathol. 2021 Apr 1;45(4):567-576. PubMed PMID: 33177339.
Aims

-Assess the frequency of LMP among CTLS and CXR detected cohorts of resected lung cancer
-Confirm the indolent nature of LMP in these cohorts compared to non-LMP adenocarcinoma and squamous cell carcinoma
-Determine if LMP correlates with overdiagnosis as did the historic entity BAC.

Collaborators

Kimberly Rieger-Christ, Ph.D.
Travis Sullivan, M.S.
Lahey Hospital and Medical Center